Published in Blood on December 01, 1995
Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL). Retrovirology (2005) 1.86
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood (2009) 1.66
Mechanism of action of interleukin-2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor. Biochem J (2003) 1.59
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol (2007) 1.45
Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood (2006) 1.33
Adult T-cell leukaemia/lymphoma. J Clin Pathol (2007) 1.32
The IL-2/IL-15 receptor systems: targets for immunotherapy. J Clin Immunol (2002) 1.30
Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis (2000) 1.26
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood (2009) 1.21
Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci U S A (2003) 1.18
Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol (2009) 1.18
Radioimmunotherapy of human tumours. Nat Rev Cancer (2015) 1.07
IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood (2007) 1.06
HTLV-1 and apoptosis: role in cellular transformation and recent advances in therapeutic approaches. Apoptosis (2008) 0.99
Adult T cell leukemia lymphoma. Front Biosci (2004) 0.97
Human T cell lymphotropic virus-associated leukemia/lymphoma. Curr Opin Oncol (2005) 0.91
Clinical trials of adult T-cell leukaemia/lymphoma treatment. Leuk Res Treatment (2012) 0.91
The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol Res (2015) 0.91
Clinical Trials and Treatment of ATL. Leuk Res Treatment (2012) 0.89
Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. Blood (2006) 0.87
Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clin Immunol (2014) 0.84
90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma. Proc Natl Acad Sci U S A (2015) 0.83
Impact of antigenemia on the bioactivity of infused anti-Tac antibody: implications for dose selection in antibody immunotherapies. Proc Natl Acad Sci U S A (1998) 0.82
131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma. Blood (2009) 0.81
Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. Proc Natl Acad Sci U S A (2007) 0.81
Molecular aspects of HTLV-I infection and adult T-cell leukaemia/lymphoma. J Clin Pathol (2007) 0.80
Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab. Nucl Med Biol (2011) 0.79
Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody. Nucl Med Biol (2011) 0.79
Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma. Cancer Biother Radiopharm (2009) 0.75
Radioimmunotherapy: promising treatment of aggressive adult T-cell leukemia? Blood (1996) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood (1994) 21.00
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol (1999) 12.42
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Factors associated with mortality in feedlot cattle: the Bruce County Beef Cattle Project. Can J Comp Med (1980) 7.74
Absence of expression of the FMR-1 gene in fragile X syndrome. Cell (1991) 7.04
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med (1995) 6.77
Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood (1980) 6.17
Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol (1985) 5.70
Spectrum of AIDS-associated malignant disorders. Lancet (1998) 5.30
A Vibrio cholerae pathogenicity island associated with epidemic and pandemic strains. Proc Natl Acad Sci U S A (1998) 4.75
Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci U S A (1986) 4.61
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Rapid isolation of DNA probes within specific chromosome regions by interspersed repetitive sequence polymerase chain reaction. Genomics (1990) 4.34
Factors associated with mortality and treatment costs in feedlot calves: the Bruce County Beef Project, years 1978, 1979, 1980. Can J Comp Med (1982) 4.34
DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet (1992) 4.22
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology (2002) 4.22
Factors associated with morbidity and mortality in feedlot calves: the Bruce County beef project, year two. Can J Comp Med (1981) 4.17
Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol (1992) 4.04
Human cytotoxic response in vitro to trinitrophenyl-modified autologous cells. I. T cell recognition of TNP in association with widely shared antigens. J Immunol (1978) 3.90
A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria. Nature (1999) 3.89
Origin of proteins in sporulation. Annu Rev Biochem (1968) 3.86
Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol (1997) 3.83
Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med (1995) 3.77
Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature (2000) 3.61
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Identification of Sonic hedgehog as a candidate gene responsible for holoprosencephaly. Nat Genet (1996) 3.50
Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol (1981) 3.46
Magnesium transport in Escherichia coli. Inhibition by cobaltous ion. J Biol Chem (1971) 3.43
Triplet repeat mutations in human disease. Science (1992) 3.35
Expression of interleukin 2 receptors on activated human B cells. J Exp Med (1984) 3.27
A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci U S A (1998) 3.26
Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet (1994) 3.22
Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med (1999) 3.18
Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med (1995) 3.11
A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell (2000) 3.03
Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet (1990) 2.96
Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med (1983) 2.96
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95
Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome. Neuron (2005) 2.82
Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med (1990) 2.82
Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol Pharmacol (1998) 2.81
The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A (1994) 2.79
Brownian dynamics of cytochrome c and cytochrome c peroxidase association. Science (1988) 2.78
Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol (1995) 2.78
Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sci U S A (1983) 2.73
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther (2013) 2.73
The human mid-size neurofilament subunit: a repeated protein sequence and the relationship of its gene to the intermediate filament gene family. EMBO J (1987) 2.72
Cytotoxic activities of gut mucosal lymphoid cells in guinea pigs. J Immunol (1978) 2.70
Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome. Nat Genet (1993) 2.69
In vitro synthesis of full-length DNA transcripts of Rous sarcoma virus RNA by viral DNA polymerase. Proc Natl Acad Sci U S A (1975) 2.68
Lymphoma classification--from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol (2000) 2.66
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood (1999) 2.65
Leu M1 and peanut agglutinin stain the neoplastic cells of Hodgkin's disease. Am J Clin Pathol (1984) 2.65
The effector cells in human peripheral blood mediating mitogen-induced cellular cytotoxicity and antibody-dependent cellular cytotoxicity. J Immunol (1976) 2.65
Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood (1999) 2.65
The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase. Nature (1992) 2.64
In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother (1996) 2.63
X-linked situs abnormalities result from mutations in ZIC3. Nat Genet (1997) 2.62
Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun (1982) 2.61
Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat Genet (2000) 2.60
Heteroduplex analysis of avian RNA tumor viruses. Proc Natl Acad Sci U S A (1977) 2.59
Musculosketal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med (1975) 2.57
Mutations in the homeodomain of the human SIX3 gene cause holoprosencephaly. Nat Genet (1999) 2.57
Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science (1988) 2.55
Mutations in TGIF cause holoprosencephaly and link NODAL signalling to human neural axis determination. Nat Genet (2000) 2.53
The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology (2000) 2.51
A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A (1994) 2.51
Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med (1996) 2.51
Thirty-year trends in incidence and age-distribution of prostate cancer in Kingston and St Andrew, Jamaica, 1978-2007. West Indian Med J (2011) 2.50
Receptors for complement and immunoglobulin on human and animal lymphoid cells. Transplant Rev (1973) 2.43
Detection of human herpesvirus 6 in tissues involved by sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). J Infect Dis (1992) 2.42
A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac. Hybridoma (1985) 2.41
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Retroviral DNA H structures: displacement-assimilation model of recombination. Cell (1982) 2.37
Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes. J Immunol Methods (1995) 2.35
The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med (1990) 2.34
The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol J (2000) 2.34
The Sézary syndrome: a malignant proliferation of helper T cells. J Clin Invest (1976) 2.32
Lymphocyte predominant Hodgkin's disease nodular subtype with coexistent "large cell lymphoma". Histological progression or composite malignancy? Am J Surg Pathol (1988) 2.31
Primary nodal marginal zone lymphomas of splenic and MALT type. Am J Surg Pathol (1999) 2.28
Epidemiology of human T-cell leukemia/lymphoma virus. J Infect Dis (1983) 2.26
Nodular lymphoma--evidence for origin from follicular B lymphocytes. N Engl J Med (1974) 2.26
Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women. Diabetes (1997) 2.26
The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect Immun (1995) 2.25
Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer (1989) 2.24
A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A (1989) 2.23
Practice-based research: lessons from community pharmacist participants. Pharmacotherapy (2001) 2.23
The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. Proc Natl Acad Sci U S A (1987) 2.22
Frequent presence of the Epstein-Barr virus in inflammatory pseudotumor. Hum Pathol (1995) 2.22
Deafness and imbalance associated with inactivation of the secretory Na-K-2Cl co-transporter. Nat Genet (1999) 2.20
Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol (2009) 2.20